Clinical Trial

E-Mindfulness Approaches for Living After Breast Cancer

Study acronym: HEAL-ABC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.
Protocol Amendment History 4 changes
notable Trial sites expanded: 364 -> 383 locations 2026-08-05
notable Trial sites expanded: 334 -> 364 locations 2026-07-03
notable Trial sites expanded: 299 -> 334 locations 2026-06-03
notable Trial sites expanded: 277 -> 299 locations 2026-04-03
Trial Details
NCT Number NCT06748222
Lead Sponsor NRG Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Breast Cancer, Depression
Enrollment 402 participants
Start Date 2025-06-27
Primary Completion 2029-02-28 (estimated)
Study Completion 2030-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-04